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Differentiation-inducing factor-1 (DIF-1) produced by Dictyostelium discoideum strongly inhibits the
proliferation of various types of cancer cells by suppression of the Wnt/b-catenin signal transduction
pathway. In the present study, we examined the effect of differentiation-inducing factor-3 (DIF-3), a
monochlorinated metabolite of DIF-1 that is also produced by D. discoideum, on human colon cancer cell
lines HCT-116 and DLD-1. DIF-3 strongly inhibited cell proliferation by arresting the cell cycle at the G0/G1
phase. DIF-3 reduced the expression levels of cyclin D1 and c-Myc by facilitating their degradation via
activation of GSK-3b in a time and dose-dependent manner. In addition, DIF-3 suppressed the expression
of T-cell factor 7-like 2, a key transcription factor in the Wnt/b-catenin signaling pathway, thereby
reducing the mRNA levels of cyclin D1 and c-Myc. Subsequently, we examined the in vivo effects of DIF-3
in Mutyh/mice with oxidative stress-induced intestinal cancers. Repeated oral administration of DIF-3
markedly reduced the number and size of cancers at a level comparable to that of DIF-1. These data
suggest that DIF-3 inhibits intestinal cancer cell proliferation in vitro and in vivo, probably by mecha-
nisms similar to those identiﬁed in DIF-1 actions, and that DIF-3 may be a potential novel anti-cancer
agent.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
The Wnt/b-catenin signaling pathway plays essential roles in
cell proliferation and differentiation, embryonic development,
maintenance of tissue homeostasis, and several other biological
processes. In cell proliferation, activation of the Wnt/b-cateninc.jp (F. Takahashi-Yanaga).
rmacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).pathway results in upregulation of its target genes, such as cyclin D1
and c-myc, which play key roles in the initiation and progression of
G1 phase in the cell cycle (1, 2).
Under physiological conditions, the activity of the Wnt/b-cat-
enin pathway is tightly controlled by the b-catenin destruction
complex in which glycogen synthase kinase-3 (GSK-3) phospho-
rylates b-catenin to induce its proteasomal degradation in coop-
eration with axin and adenomatous polyposis coli (APC). However,
mutations in components of the destruction complex or b-catenin
itself can lead to hyperactivation of theWnt/b-catenin pathway and
promotion of cancer development (3e7). Indeed, the Wnt/b-nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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as well as in other types of malignant tumors (8e12).
Differentiation-inducing factors (DIFs) were identiﬁed in D.
discoideum as morphogens required for differentiation to stalk cells
(13, 14), and have been shown to strongly inhibit the proliferation
of mammalian cells, regardless of whether they are normal or
cancerous (7,15e25). DIF-1 [1-(3, 5-dichloro-2, 6-dihydroxy-4-
methoxyphenyl)-1-hexanone] was the ﬁrst identiﬁed member of
the DIF family. We have reported that DIF-1 activates GSK-3b to
phosphorylate and induce degradation of cyclin D1, c-Myc, and b-
catenin, which leads to inhibition of cyclin D1 and c-Myc trans-
cription (16e23). Recently, we found that DIF-1 inhibits the
expression of T-cell factor 7-like 2 (TCF7L2), a key transcription
factor in the induction of Wnt target genes, which might explain
why DIF-1 suppresses the proliferation of colon cancer cells with
constitutive activation of b-catenin signaling (22e24). Indeed,
repeated oral administration of DIF-1 inhibits oxidative stress-
induced intestinal tumor growth in vivo in a dose-dependent
manner (24).
D. discoideum metabolizes DIF-1 to the monochlorinated
analogue DIF-3 [1-(3-chloro-2, 6-dihydroxy-4-methoxyphenyl)-1-
hexanone] (14). We have previously reported that DIF-3 also
exerts a strong antiproliferative effect on the human cervical cancer
cell line HeLa by inducing cyclin D1 degradation and inhibiting
cyclin D1mRNA expression (16). In some types of cancer cells, DIF-3
has been reported to exert more powerful antiproliferative effects
than DIF-1 (16, 25).
Therefore, in the present study, we examined whether DIF-3
exerts antiproliferative effects on human colon cancer cell lines
HCT-116 and DLD-1, which exhibit constitutive inactivation of the
b-catenin destruction complex, and analyzed downstream com-
ponents of the Wnt/b-catenin signal transduction pathway.
Furthermore, we examined the effect of repeated oral adminis-
tration of DIF-3 on intestinal cancer in Mutyh-deﬁcient (Mutyh/)
mice (26), which lack the MutY homolog (MUTYH), a mammalian
DNA glycosylase that initiates base excision repair, and are thus
susceptible to oxidative stress-induced carcinogenesis (27e29).
2. Materials and methods
2.1. Chemicals and antibodies
DIF-1 and DIF-3 were synthesized as described previously (13,
14). MG132 was purchased from the Peptide Institute (Osaka,
Japan). SB216763 was purchased from BIOMOL International
(Farmingdale, NY, USA). A monoclonal and a polyclonal anti-cyclin
D1 antibodys were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). A monoclonal anti-c-Myc antibody was
purchased from Cell Signaling Technology (Danvers, MA, USA). A
monoclonal anti-a-tubulin antibody was purchased from Calbio-
chem (Darmstadt, Germany). A monoclonal anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody was purchased from
Abcam (Cambridge, UK). A monoclonal anti-TCF7L2 antibody was
purchased fromMerckMillipore (Billerica, MA, USA). A monoclonal
anti-b-catenin antibody was purchased from BD Biosciences (San
Jose, CA, USA).
2.2. Cell culture
Human colon cancer cell lines HCT-116 (expressing wild-type
APC and mutant b-catenin) and DLD-1 (expressing mutant APC
and wild-type b-catenin) were cultured in Dulbecco's modiﬁed
Eagle's medium (Sigma, St. Louis, MO, USA) supplementedwith 10%
fetal bovine serum, 100 U/mL penicillin G, and 0.1 mg/mL
streptomycin.2.3. Cell proliferation assay
HCT-116 or DLD-1 cells were seeded in 24-well plates (5  104
cells/well) and treated with various concentrations of DIF-1 or DIF-
3 for the indicated periods. Cells were harvested by trypsin/EDTA
treatment and counted using an automated cell counter (TC10; Bio-
Rad, Tokyo, Japan).
2.4. Flow cytometry
Cells were suspended in a hypotonic solution containing 50 mg/
mL propidium iodide (PI), 0.1% sodium citrate, and 0.1% Triton X-
100. PI-stained samples (1  105 cells) were analyzed for ﬂuores-
cence with a FACSCalibur (BectoneDickinson, Franklin Lakes, NJ,
USA).
2.5. Western blotting
Samples were separated by 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and then transferred to a poly-
vinylidene ﬂuoride membrane using a semidry transfer system (1 h
at 12 V). Immunoreactive proteins were visualized by treatment
with a detection reagent (LumiGLO; Cell Signaling Technology).
Densitometric analysis was performed using ImageJ software
(National Institutes of Health, Bethesda, MD, USA).
2.6. Real-time quantitative RT-PCR
Total RNA was isolated using TRIzol reagent (Invitrogen).
Reverse transcription was carried out using a High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Life Technologies,
DriveRockville, MD, USA). Quantitative PCR was performed using
TaqMan® Universal Master Mix II, TaqMan® Gene Expression
Assays (cyclin D1, Hs0075553_m1; c-Myc, Hs00153408_m1;
GAPDH, Hs99999905_m1), and an ABI 7500 Real-Time PCR System
(Applied Biosystems). PCR conditions were initial denaturation for
10 min at 95 C, followed by 40 cycles of 15 s at 95 C and 60 s at
60 C. The expression levels of target genes were calculated from
the DDCt values. GAPDH was used as an internal control.
2.7. Plasmids
TOPﬂash (TCF reporter plasmid) and FOPﬂash (negative control
for TOPﬂash) were purchased from Upstate Biotechnology (Lake
Placid, NY, USA). A cyclin D1 pGL3 basic luciferase reporter plasmid
was a generous gift fromDrs. O. Tetsu and F. McCormick (University
of California, San Francisco, CA, USA). A TCF7L2 overexpression
plasmid was generated as described previously (22).
2.8. Luciferase reporter assay
Cells were transfected with luciferase reporter plasmids and
pRL-SV40, a Renilla luciferase expression plasmid as a control for
transfection efﬁciency, using Lipofectamine Plus reagent (Invi-
trogen, Life Technologies). After 24 h, the cells were stimulated
with DIF-3 for the indicated periods. Luciferase activity was
determined with a luminometer (Lumat LB 9507; Berthold Tech-
nologies, Barsinghausen, Germany) and normalized against Renilla
luciferase activity.
2.9. Intestinal tumor model
Induction of intestinal tumor formation (adenomas and carci-
nomas) in Mutyh/ mice was carried out by a previously reported
method (26). Brieﬂy, KBrO3 dissolved in water at a concentration of
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weeks of age, the mice were randomly divided into two groups
(eight mice including four male mice and four female mice in each
group). Mice in the test group were orally administered DIF-3
suspended in a 0.25% methylcellulose solution once a day for 5
days/week over 4 weeks. Control mice received the vehicle only.
The body weight of the mice was monitored weekly. At 20 weeks of
age, all mice were sacriﬁced to obtain blood and intestinal samples.
Blood samples were analyzed for blood cell counts by a Celltac-
alpha MEK-6358 (Nihon Kohden, Tokyo, Japan). Intestines were
ﬁxed in 4% formaldehyde, and the tumors were observed under a
microscope. Images of the tumors were obtained and analyzed
using ImageJ software.2.10. Histological analyses
Tumors of 1.0e2.0 mm in diameter, which had developed
3.0e5.0 cm distal from the pylorus, were resected from
formaldehyde-ﬁxed intestines. Samples were embedded in parafﬁn
and subjected to hematoxylin-eosin (HE) and immunohistochem-
ical staining. Brieﬂy, the sections were incubated with the
anti-TCF7L2 antibody (1:2000 dilution) or polyclonal anti-cyclin D1
antibody (1:100 dilution) overnight at 4 C, followed by incubation
with the secondary antibody (Histoﬁne, Nichirei, Tokyo, Japan) for
1 h. The sections were then analyzed with a Biozero microscope
(Keyence, Osaka, Japan).Fig. 1. Antiproliferative effect of DIF-3 on human colon cancer cells. (A) Cell proliferation
indicated concentrations of DIF-1 or DIF-3 for the indicated periods. (B) Flow cytometric anal
treatment. The cells were stained with PI and nuclear ﬂuorescence was measured by ﬂow cy
are the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.0012.11. Statistical analyses
Results are expressed as the mean ± standard error of the mean
(SEM). Statistical analysis of differences between two mean values
was performed using the Student's t-test. Multiple mean values
were compared by one-way analysis of variance with the Dunnett's
multiple comparison test (GraphPad Prism 5.0; GraphPad Software,
La Jolla, CA, USA). P-values of less than 0.05 were considered sta-
tistically signiﬁcant.
2.12. Ethics statement
This study protocol was approved by the Committee of Ethics on
Animal Experiments at Kyushu University (Permit Number: A22-
046-0). Animal handling and procedures were carried out in
compliance with the Guidelines for Animal Experiments, Kyushu
University, and the Law (No. 105) and Notiﬁcation (No. 6) of the
Japanese Government. All surgeries were performed under sodium
pentobarbital anesthesia while making all efforts to minimize
suffering.
3. Results
3.1. Antiproliferative effect of DIF-3 on human colon cancer cells
First, we examined the effect of DIF-3 on the proliferation of the
human colon cancer cell lines, HCT-116 and DLD-1. As shown inassay. HCT-116 and DLD-1 cells were seeded on a 24-well plate and treated with the
ysis. Cells were treated with DIF-3 (30 mM) for 24 h and then harvested by trypsin/EDTA
tometry. The percentages of cells in the various cell cycle phases are shown. The results
vs. control.
Fig. 2. DIF-3 suppresses the expression of cyclin D1 in HCT-116 cells. (A) Time course. HCT-116 cells were treated with or without DIF-3 (30 mM) for the indicated periods. (B) Dose
dependency. HCT-116 cells were treated with the indicated concentrations of DIF-1 or DIF-3 for 24 h. Protein samples were subjected to Western blot analysis using anti-cyclin D1
and anti-a-tubulin antibodies. Protein bands were quantiﬁed and are shown as the percentage of the control level at time 0. The results are the mean ± SEM of three independent
experiments. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control.
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manner in both cell lines. The effect of DIF-3 was slightly stronger
than that of DIF-1, and HCT-116 cells were more sensitive to DIF-3
than DLD-1 cells. Flow cytometry showed that treatment with
DIF-3 signiﬁcantly increased the number of cells in G0/G1 phase and
decreased those in S phase in both cell lines (Fig. 1B). Although DIF-
3 also signiﬁcantly increased the number of cells in G2 phase when
HCT-116 cells were employed, this effect was not observed by using
DLD-1 cells. These results indicated that DIF-3 arrested the cell
cycle at G0/G1 phase.Fig. 3. DIF-3 suppresses the expression of c-Myc in HCT-116 cells. (A) Time course. Cells were
Cells were treated with the indicated concentrations of DIF-1 or DIF-3 for 24 h. Protein sa
tibodies. Protein bands were quantiﬁed and are shown as the percentage of the control level
**P < 0.01, ***P < 0.001 vs. control.3.2. DIF-3 induces proteolysis of cyclin D1 and c-Myc in HCT-116
cells via activation of GSK-3b
Because DIF-3 induces cell cycle arrest at G0/G1 phase by
suppressing cyclin D1 expression in HeLa cells (16), we examined
the effect of DIF-3 on the expression of cyclin D1 in HCT-116 cells, in
which b-catenin is constitutively active. As shown in Fig. 2A and B, a
rapid and marked reduction in the amount of cyclin D1 protein in a
time and dose-dependent manner was induced by DIF-3. Further-
more, treatment with DIF-3 resulted in a strong reduction in thetreated with or without DIF-3 (30 mM) for the indicated periods. (B) Dose dependency.
mples were subjected to Western blot analysis using anti-c-Myc and anti-GAPDH an-
at time 0. The results are the mean ± SEM of three independent experiments. *P < 0.05,
Fig. 4. DIF-3 induces degradation of cyclin D1 and c-Myc in HCT-116 cells. Cells pretreatedwithMG132 for 1 h (A and B) or SB216763 for 3 h (C and D)were treatedwith or without DIF-3
(30 mM) for 1 h. Sampleswere subjected toWestern blot analysis using anti-cyclin D1 and anti-a-tubulin antibodies (A and C) or anti-c-Myc and GAPDHantibodies (B andD). Protein bands
were quantiﬁed and are shown as the percentages of the degraded amounts. Values are the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 vs. control.
Fig. 5. DIF-3 represses the expression of cyclin D1 and c-Myc mRNA without decreasing the amount of b-catenin protein in HCT-116 cells. (A) mRNA expression. Cells were treated
with or without 30 mM DIF-3 for 24 h. Total RNA was isolated and subjected to quantitative PCR to analyze cyclin D1, c-Myc, and GAPDH mRNA expression. The levels of mRNA
expression were quantiﬁed and are shown as the percentage of the control level at time 0. (B) b-catenin protein. Cells were treated with or without DIF-3 (30 mM) for 24 h. Protein
samples were subjected to Western blot analysis using anti-b-catenin and anti-GAPDH antibodies. Protein bands were quantiﬁed and are shown as the percentage of the control
level at time 0. Values are the mean ± SEM of three independent experiments. **P < 0.01, ***P < 0.001 vs. control.
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(Fig. 3A and B). DIF-3 decreased the expression of cyclin D1 and c-
Myc to a level comparable to the reduction induced by DIF-1
(Figs. 2B and 3B).Fig. 6. DIF-3 inhibits the expression of TCF7L2 and suppresses TCF-dependent transcription
the indicated periods. (B) Dose dependency. Cells were treated with or without the indicate
blot analysis using anti-TCF7L2 and anti-GAPDH antibodies. Protein bands were quantiﬁed an
dependent transcriptional activity. TOPFlash or FOPFlash were co-transfected with pRL-SV40
for 12 h. Luciferase activity is shown as the percentage of the control level at time 0. (D) Egr
were subjected to Western blot analysis using anti-Egr-1 and anti-GAPDH antibodies. Protein
(E) TCF7L2 overexpression. The pcDNA3 or pcDNA3/TCF7L2 plasmid was transfected into H
Protein samples were subjected to Western blotting using anti-TCF7L2 and anti-GAPDH ant
amount of TCF7L2. (F) Cyclin D1 promoter activity using TCF7L2-overexpressed cells. Cyclin
SV40 into HCT-116 cells. After 24 h of incubation, the cells were treated with or without DIF-
Values are the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01 vs. coTo determine themechanisms of the DIF-3-induced reduction in
the expression levels of cyclin D1 and c-Myc, we examined the
effect of MG132, a ubiquitin-proteasome inhibitor, on the actions of
DIF-3. As shown in Fig. 4A and B, pretreatment with MG132in HCT-116 cells. (A) Time course. Cells were treated with or without DIF-3 (30 mM) for
d concentrations of DIF-1 or DIF-3 for 24 h. Protein samples were subjected to Western
d are shown as the percentage of the control level at time 0. (C) Effects of DIF-3 on TCF-
into HCT-116 cells. After 24 h of incubation, the cells were stimulated with 20 mMDIF-3
-1 protein. Cells were treated with or without DIF-3 (30 mM) for 24 h. Protein samples
bands were quantiﬁed and are shown as the percentage of the control level at time 0.
CT-116 cells. After 24 h, the cells were treated with or without DIF-3 (20 mM) for 12 h.
ibodies. Protein bands were quantiﬁed and shown as percentage of the decrease in the
D1 promoter and pcDNA3 or pcDNA3/TCF7L2 plasmids were co-transfected with pRL-
3 (20 mM) for 12 h. Data are shown as percentages of the reduction in luciferase activity.
ntrol.
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accelerated ubiquitin-proteasome-dependent proteolysis of cyclin
D1 and c-Myc. Because GSK-3b has been reported to trigger
proteolysis of cyclin D1 and c-Myc (30, 31), we determinedwhether
GSK-3bwas involved in the DIF-3-induced degradation of cyclin D1
and c-Myc using the GSK-3b inhibitor SB216763. As shown in
Fig. 4C and D, pretreatment with SB216763 (20 mM for 3 h) atten-
uated the effect of DIF-3, indicating the involvement of GSK-3b in
the DIF-3-induced degradation of cyclin D1 and c-Myc.
3.3. DIF-3 suppresses TCF-mediated transcription in HCT-116 cells
Interestingly, DIF-3 not only accelerated the proteolysis of cyclin
D1 and c-Myc, but also reduced their mRNA levels (Fig. 5A). These
effects could not be explained by inhibition of b-catenin, because
the mutant b-catenin expressed in HCT-116 cells is resistant to the
b-catenin destruction complex. In fact, DIF-3 had no effect on the
expression level of b-catenin (Fig. 5B).
To solve this enigma, we examined the effect of DIF-3 on the
expression of TCF7L2, a key transcription factor in the Wnt/b-
catenin signaling pathway. The amount of TCF7L2 increased
gradually over time in control cells, but it was markedly reduced
by DIF-3 in a time and dose-dependent manner (Fig. 6A and B).
Consistently, the TCF-mediated transcription measured by the
TOPﬂash assay was strongly suppressed in cells treated with DIF-3
(Fig. 6C). Furthermore, we investigated the effect of DIF-3 on early
growth response-1 (Egr-1), because we had previously found that
DIF-1 suppresses TCF7L2 expression by decreasing the expressionFig. 7. Effect of DIF-3 in DLD-1 cells. DLD-1 cells were treated with the indicated concentrat
using anti-cyclin D1 (A), anti-c-Myc (B), or anti-TCF7L2 (C) antibodies. Protein bands were
mean ± SEM of three independent experiments. **P < 0.01, ***P < 0.001 vs. control.of Egr-1, a transcription factor of TCF7L2 (22). As shown in Fig. 6D,
treatment with DIF-3 for 24 h reduced the protein level of Egr-1.
Next, we overexpressed TCF7L2 to conﬁrm its involvement in the
action of DIF-3. As shown in Fig. 6E, stimulation with DIF-3 for 12 h
reduced the expression level of TCF7L2 in cells transfected with the
empty pcDNA3 vector, whereas this effect was attenuated in cells
transfected with pcDNA3/TCF7L2. Subsequently, we examined the
effect of DIF-3 on cyclin D1 promoter activity. Compared with cells
transfected with the empty pcDNA3 vector, the effect of DIF-3 was
attenuated in cells overexpressing TCF7L2 (Fig. 6F). These results
suggested that theDIF-3-induced reduction of TCF7L2was associated
with the transcriptional inhibitionofcyclinD1mRNAinHCT-116cells.
3.4. DIF-3 inhibits Wnt/b-catenin signaling pathway-related
proteins in DLD-1 cells
We next examined the mechanism by which DIF-3 inhibited the
proliferation of DLD-1 cells in which the function of the b-catenin
destruction complex is impaired by mutant APC. As demonstrated
in Fig. 7, similar to its effect on HCT-116 cells, DIF-3 markedly
reduced the expression levels of cyclin D1, c-Myc, and TCF7L2 in
DLD-1 cells.
3.5. Inhibitory effect of DIF-3 on oxidative stress-induced tumors in
Mutyh/ mice
To investigate the anti-tumor effect of DIF-3 in vivo, we used
mice deﬁcient for MUTYH (Mutyh/), an enzyme that prevents theions of DIF-1 or DIF-3 for 24 h. Protein samples were subjected to Western blot analysis
quantiﬁed and are shown as the percentage of the control at time 0. Values are the
N. Kubokura et al. / Journal of Pharmacological Sciences 127 (2015) 446e455 453formation of oxidative stress-induced DNA lesions. Previous studies
have shown that MUTYH deﬁciency may be involved in the
development of colorectal adenomas and carcinomas in humans
(27e29). Furthermore, we have previously reported dramatic in-
creases in the occurrence of oxidative stress-induced carcinomas in
the small intestines of Mutyh/ mice in comparison with normal
mice (24, 26).
Twelve weeks of treatment with 0.2% KBrO3, a strong oxidant,
induced numerous intestinal tumors inMutyh/mice (Fig. 8A). To
evaluate the effect of DIF-3 on these tumors, DIF-3 or the vehicle
only were orally administered to Mutyh/ mice for 4 weeks.Fig. 8. Effect of DIF-3 on intestinal tumors induced by KBrO3 in Mutyh/ mice. (A) Upper p
diameter. Scale bar: 1 cm. Lower left panel: tumor numbers were plotted for each mouse. L
mouse. Horizontal bars indicate the mean of each group (n ¼ 8). *P < 0.05, **P < 0.01 vs. veh
were stained with anti-TCF7L2 (upper) or anti-cyclin D1 (lower) antibodies. Black square ind
tumor sample and percentages of stained nuclei was shown. Values are shown as the meaTreatment with DIF-3 (150 mg/kg/day for 4 weeks) markedly
reduced the number of intestinal tumors, especially the number of
large tumors with a diameter of >2.0 mm (Fig. 8A). There were no
differences in the appearance, activity, body weight, or blood cell
counts between DIF-3-treated mice and the controls
(Supplementary Figure 1).
Subsequently, we performed immunohistochemical analyses of
the tumors. As shown in Fig. 8B, the numbers of TCF7L2-and cyclin
D1-positive nuclei in tumors were signiﬁcantly decreased in the
DIF-3-treated group compared with the control, which was
consistent with the in vitro experimental results.anels: proximal region of the small intestines. Arrows indicate tumors of >2.0 mm in
ower right panel: the number of tumors of >2.0 mm in diameter was plotted for each
icle. (B) Histological analyses of intestinal tumors. Tumor samples (n ¼ 5 in each group)
icates the magniﬁed area. Scale bar: 50 mm. More than 100 nuclei were counted in each
n ± SEM of ﬁve individual samples. **P < 0.01 vs. vehicle.
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Based on our earlier investigations on the DIF family, we
hypothesized that DIFs arrest the cell cycle by inducing degradation
of proteins essential for cell proliferation such as cyclin D1 and b-
catenin. Degradation of b-catenin further prevents TCF-mediated
transcription of several genes required for cell proliferation
(15e21). According to this hypothesis, the action of DIFs appears to
require an intact b-catenin destruction complex. Therefore, we
speculated that DIFs would be unable to inhibit colorectal cancer
cell proliferation because of the impaired functions of the b-catenin
destruction complex in most colorectal cancers, including MUTYH-
associated polyposis, which are caused by mutations in its com-
ponents such as b-catenin and APC (7e12,27e29). However, in
contrast to this hypothesis, we found that DIF-1 strongly inhibited
the proliferation of colorectal cancer cells through suppression of
TCF7L2 transcription by downregulation of Egr-1 levels in the
nucleus, resulting in the inhibition of the Wnt/b-catenin signaling
pathway (22). Consistent with our study, Saegusa et al (32) re-
ported that TCF7L2 promoter activity is regulated by Egr-1. Ac-
cording to these observations, downregulation of Egr-1 expression
might be one of the important actions of DIF-1 in suppression of the
Wnt/b-catenin signaling pathway.
Thus,wedeterminedwhetheronlyDIF-1 inhibits theproliferation
of colon cancer cells irrespective of the b-catenin destruction
complex or whether this action is shared by other DIF family mem-
bers, particularly DIF-3, because DIF-3 exerts stronger effects than
DIF-1 on suppression of human cancer cell proliferation (16, 25).
Speciﬁcally, we investigated whether DIF-3 can inhibit the prolifer-
ation of colorectal cancers with impaired b-catenin destruction ma-
chinery with respect to its effect on TCF7L2. DIF-1 and DIF-3
demonstrated essentially the same effects. DIF-3 also had an anti-
proliferative effect on HCT-116 and DLD-1 cells, and reduced the
expression levels of cyclin D1, c-Myc, and TCF7L2 despite the mutant
b-catenin or APC. In addition, DIF-3, but not DIF-1, led to a signiﬁcant
increase in the number of HCT-116 cells in G2 phase, whereas this
effectwasnot seen inDLD-1,HeLa orbovine aortic endothelial cells in
which proliferation is strongly inhibited by DIF-3 (16). Therefore, cell
cycle arrest atG2/Mphasemaynot be essential for the action ofDIF-3.
Moreover, DIF-3 exhibited an anti-tumor effect in Mutyh/ mice, a
useful animal model for colorectal adenocarcinoma, without
apparent adverse drug reactions. Oral administration of DIF-3
markedly reduced the number of intestinal tumors, especially that
of large tumors (>2.0 mm in diameter), suggesting that DIF-3 has
potential as a novel anti-cancer agent.
We expected that the anti-tumor effect of DIF-3 on colorectal
cancer cells, if any, would be stronger than that of DIF-1, because it
has been reported that DIF-3 has more powerful effects than DIF-1
to inhibit the proliferation of HeLa cells (16) and the human leu-
kemia cell line K562 (25). However, in the present study, the efﬁ-
cacy of DIF-3was comparable to that of DIF-1 in HCT-116 and DLD-1
cells. Moreover, the in vivo effects of DIF-3 in the oxidative stress-
induced intestinal tumor model appeared to be weaker than
those of DIF-1 (24). Although we cannot exactly explain the reason
for these results, we speculate that the presence or absence of
mutations in the b-catenin destruction complex could have caused
the difference in sensitivity to DIF-1 and DIF-3 between the cell
lines. The b-catenin destruction complex is impaired in HCT-116
and DLD-1 cells, but it is intact in HeLa and K562 cells. Therefore,
the anti-tumor effect of DIF-3 may be more dependent on sup-
pression of b-catenin signaling than that of DIF-1. Further studies
are required to examine this issue.
Similar to DIF-1, we assume that DIF-3 is a potential lead com-
pound as a novel oral anti-cancer drug with unique mechanisms of
action. However, to identify and develop an optimal compound, it iscritical to identify the target molecule(s) of the DIF family. Despite
our and others' efforts, the target molecule(s) of the DIF family,
which mediate their antiproliferative effect on cancer cells, have
not been identiﬁed. Shimizu et al. have suggested that PDE1
(calmodulin-dependent cyclic nucleotide phosphodiesterase) may
be a target of DIFs (33). In addition, we have reported that mito-
chondrial malate dehydrogenase may be one of the target mole-
cules of DIF-1 (34). However, the effects of DIFs on these molecules
does not appear to correlate with their antiproliferative effects (33,
34). Identiﬁcation of these target molecule(s) may not only reveal
the precise mechanisms of action of the DIF family, but also facili-
tate the design of novel anticancer drugs with unique mechanisms
of action.Conﬂicts of interest
The authors indicated no potential conﬂicts of interest.Acknowledgments
This work was supported by Kakenhi grants from the Japan
Society for the Promotion of Science (21590284 and 25460334 to
FTY).Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.jphs.2015.03.005.References
(1) Sherr CJ. Cancer cell cycles. Science. 1996;274:1672e1677.
(2) Meyer N, Penn LZ. Reﬂecting on 25 years with MYC. Nat Rev Cancer. 2008;8:
976e990.
(3) Barnes DM, Gillett CE. Cyclin D1 in breast cancer. Brest Cancer Res Treat.
1998;52:1e15.
(4) Nesbit CE, Tersak JM, Prochownik EV. MYC oncogenes and human neoplastic
disease. Oncogene. 1999;18:3004e3016.
(5) Utsunomiya T, Doki Y, Takemoto H, Shiozaki H, Yano M, Sekimoto M, et al.
Correlation of b-catenin and cyclin D1 expression in colon cancers. Oncology.
2001;61:226e233.
(6) Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and
abnormal functions. Endocrinology. 2004;145:5439e5447.
(7) Takahashi-Yanaga F, Sasaguri T. Drug development targeting the glycogen
synthase kinase-3b (GSK-3b)-mediated signal transduction pathway: in-
hibitors of the Wnt/b-catenin signaling pathway as novel anticancer drugs.
J Pharmacol Sci. 2009;109:179e183.
(8) Logan CY, Nusse R. The Wnt signaling pathway in development and disease.
Annu Rev Cell Dev Biol. 2004;20:781e810.
(9) Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, et al.
Activation of b-catenin-Tcf signaling in colon cancer by mutations in b-catenin
or APC. Science. 1997;275:1787e1790.
(10) Satoh S, Daigo Y, Furukawa Y, Kato T, Miwa N, Nishiwaki T, et al. AXIN1
mutations in hepatocellular carcinomas, and growth suppression in cancer
cells by virus-mediated transfer of AXIN1. Nat Genet. 2000;24:245e250.
(11) McDonald SA, Preston SL, Lovell MJ, Wright NA, Jankowski JA. Mechanisms of
disease: from stem cells to colorectal cancer. Nat Clin Pract Gastroenterol
Hepatol. 2006;3:267e274.
(12) Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt
pathway. Oncogene. 2006;25:7531e7537.
(13) Morris HR, Taylor GW, Masento MS, Jermyn KA, Kay RR. Chemical structure of
the morphogen differentiation inducing factor from Dictyostelium discoideum.
Nature. 1987;328:811e814.
(14) Morris HR, Masento MS, Taylor GW, Jermyn KA, Kay RR. Structure elucidation
of two differentiation inducing factors (DIF-2 and DIF-3) from the cellular
slime mould Dictyostelium discoideum. Biochem J. 1988;249:903e906.
(15) Miwa Y, Sasaguri T, Kosaka C, Taba Y, Ishida A, Abumiya T, et al. Differentia-
tion-inducing factor-1, a morphogen of dictyostelium, induces G1 arrest and
differentiation of vascular smooth muscle cells. Circ Res. 2000;86:68e75.
(16) Takahashi-Yanaga F, Taba Y, Miwa Y, Kubohara Y, Watanabe Y, Hirata M, et al.
Dictyostelium differentiation-inducing factor-3 activates glycogen synthase
kinase-3b and degrades cyclin D1 in mammalian cells. J Biol Chem. 2003;278:
9663e9670.
N. Kubokura et al. / Journal of Pharmacological Sciences 127 (2015) 446e455 455(17) Yasmin T, Takahashi-Yanaga F, Mori J, Miwa Y, Hirata M, Watanabe Y, et al.
Differentiation-inducing factor-1 suppresses gene expression of cyclin D1 in
tumor cells. Biochem Biophys Res Commun. 2005;338:903e909.
(18) Matsuzaki E, Takahashi-Yanaga F, Miwa Y, Hirata M, Watanabe Y, Sato N, et al.
Differentiation-inducing factor-1 alters canonical Wnt signaling and sup-
presses alkaline phosphatase expression in osteoblast-like cell lines. J Bone
Min Res. 2006;21:1307e1316.
(19) Takahashi-Yanaga F, Mori J, Matsuzaki E, Watanabe Y, Hirata M, Miwa Y, et al.
Involvement of GSK-3b and DYRK1B in differentiation-inducing factor-3-
induced phosphorylation of cyclin D1 in HeLa cells. J Biol Chem. 2006;281:
38489e38497.
(20) Mori J, Takahashi-Yanaga F, Miwa Y, Watanabe Y, Hirata M, Morimoto S, et al.
Differentiation-inducing factor-1 induces cyclin D1 degradation through the
phosphorylation of Thr286 in squamous cell carcinoma. Exp Cell Res.
2005;310:426e433.
(21) Yoshihara T, Takahashi-Yanaga F, Shiraishi F, Morimoto S, Watanabe Y,
Hirata M, et al. Anti-angiogenic effects of differentiation-inducing factor-1
involving VEGFR-2 expression inhibition independent of the Wnt/b-catenin
signaling pathway. Mol Cancer. 2010;9:245.
(22) Jingushi K, Takahashi-Yanaga F, Yoshihara T, Shiraishi F, Watanabe Y,
Hirata M, et al. DIF-1 inhibits the Wnt/b-catenin signaling pathway by
inhibiting TCF7L2 expression in colon cancer cell lines. Biochem Pharmacol.
2012;83:47e56.
(23) Jingushi K, Nakamura T, Takahashi-Yanaga F, Matsuzaki E, Watanabe Y,
Yoshihara T, et al. Differentiation-inducing factor-1 suppresses the expression
of c-Myc in the human cancer cell lines. J Pharmacol Sci. 2013;121:103e109.
(24) Takahashi-Yanaga F, Yoshihara T, Jingushi K, Igawa K, Tomooka K,
Watanabe Y, et al. DIF-1 inhibits tumor growth in vivo reducing phosphory-
lation of GSK-3b and expressions of cyclin D1 and TCF7L2 in cancer model
mice. Biochem Pharmacol. 2014;89:340e348.
(25) Kubohara Y. Effects of differentiation-inducing factors of Dictyostelium dis-
coideum on human leukemia K562 cells: DIF-3 is the most potent anti-
leukemic agent. Eur J Pharmacol. 1999;381:57e62.(26) Sakamoto K, Tominaga Y, Yamauchi K, Nakatsu Y, Sakumi K, Yoshiyama K,
et al. MUTYH-deﬁcient mice are susceptible to spontaneous and oxidative
stress induced intestinal tumorigenesis. Cancer Res. 2007;67:6599e6604.
(27) Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, Williams GT,
et al. Inherited variants of MYH associated with somatic G: C–>T: a mutations
in colorectal tumors. Nat Genet. 2002;30:227e232.
(28) Sampson JR, Dolwani S, Jones S, Eccles D, Ellis A, Evans DG, et al. Autosomal
recessive colorectal adenomatous polyposis due to inherited mutations of
MYH. Lancet. 2003;362:39e41.
(29) Sieber OM, Lipton L, Crabtree M, Heinimann K, Fidalgo P, Phillips RK, et al.
Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line
mutations in MYH. N Engl J Med. 2003;348:791e799.
(30) Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on
threonine-286 prevents its rapid degradation via the ubiquitin-proteasome
pathway. Genes Dev. 1997;11:957e972.
(31) Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3
controls c-myc proteolysis and subnuclear localization. J Biol Chem.
2003;278:51606e51612.
(32) Saegusa M, Hashimura M, Kuwata T, Hamano M, Watanabe J, Kawaguchi M,
et al. Transcription factor Egr1 acts as an upstream regulator of b-catenin
signaling through up-regulation of TCF4 and p300 expression during trans-
differentiation of endometrial carcinoma cells. J Pathol. 2008;216:521e532.
(33) Shimizu K, Murata T, Tagawa T, Takahashi K, Ishikawa R, Abe Y, et al.
Calmodulin-dependent cyclic nucleotide phosphatase (PDE1) is a pharmaco-
logical target of differentiation-inducing factor-1, an antitumor agent isolated
from Dictyostelium. Cancer Res. 2004;64:2568e2571.
(34) Matsuda T, Takahashi-Yanaga F, Yoshihara T, Maenaka K, Watanabe Y,
Miwa Y, et al. Dictyostelium differentiation-inducing factor-1 binds to mito-
chondrial malate dehydrogenase and inhibits its activity. J Pharmacol Sci.
2010;112:320e326.
